Compare Amphastar Pharmaceuticals Inc (AMPH) vs Meta Platforms Inc (META) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Meta Platforms Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Meta Platforms Inc trades at $599.98 (market cap $1.52T). The key difference: Meta Platforms Inc is far larger — about 1759.4× Amphastar Pharmaceuticals Inc's market cap, and Meta Platforms Inc pays a 0.35% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | META | |
|---|---|---|
Market Cap | $863.95M | $1.52T |
Sector | Health | Media |
52-Week High | $30.81 | $790.00 |
52-Week Low | $16.87 | $525.72 |
Enterprise Value | $1.26B | $1.54T |
Volume | — | 24,093,972 |
Dividend Yield | — | 0.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
META stock trades at $599.12, up 1.19% in the last 24 hours, with a bearish technical signal despite strong fundamentals. Recent earnings show a Q2 2026 miss but beats in prior quarters, while revenue grew to $201.0B in 2025. The company launched its Muse Spark AI model, driving positive sentiment, but faces legal risks from a Massachusetts youth addiction lawsuit ruled on April 10, 2026.
Outlook remains positive with a consensus price target of $761.95, reflecting 79% analyst buy ratings. Key opportunities include AI monetization and revenue growth, balanced by regulatory risks and high capital expenditures. Investors should weigh robust profitability against potential legal and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →
